Meta Mergim, Zimmer Collin, Fuchs Natalie, Zecher Maximilian Johannes, Lahu Albin, Schirmeister Tanja
Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, Staudingerweg 5, 55128 Mainz Germany.
ACS Med Chem Lett. 2024 Jun 4;15(6):837-844. doi: 10.1021/acsmedchemlett.4c00050. eCollection 2024 Jun 13.
Cathepsin S (catS) is a member of the cysteine protease family with limited tissue distribution, which is predominantly found in antigen-presenting cells. Due to overexpression and overactivity of catS in numerous cancers, inhibition of catS is supposed to improve the antitumor response. Here, we explore the potential of small-molecule catS inhibitors emphasizing their in vitro pharmacodynamics and pharmacokinetics. Membrane permeability of selected inhibitors was measured with a Parallel Artificial Membrane Permeation Assay and correlated to calculated physicochemical parameters and inhibition data. The binding kinetics and inhibition types of potent and selective new inhibitors with unexplored warheads were investigated. Our unique approach involves reversible masking of these potent warheads, allowing for further customization without compromising affinity or selectivity. The most promising inhibitors in this study include covalent aldehyde and ketone derivatives reversibly masked as hydrazones as potential candidates for therapeutic interventions targeting catalytic enzymes and modulating the immune response in cancer.
组织蛋白酶S(catS)是半胱氨酸蛋白酶家族的成员,其组织分布有限,主要存在于抗原呈递细胞中。由于catS在多种癌症中过度表达和过度活跃,抑制catS有望改善抗肿瘤反应。在此,我们探索小分子catS抑制剂的潜力,重点关注其体外药效学和药代动力学。使用平行人工膜渗透试验测量所选抑制剂的膜通透性,并将其与计算出的物理化学参数和抑制数据相关联。研究了具有未探索弹头的强效和选择性新抑制剂的结合动力学和抑制类型。我们独特的方法涉及对这些强效弹头进行可逆掩蔽,以便在不影响亲和力或选择性的情况下进行进一步定制。本研究中最有前景的抑制剂包括可逆地掩蔽为腙的共价醛和酮衍生物,作为靶向催化酶和调节癌症免疫反应的治疗干预潜在候选物。